Residual endogenous corticosteroid production in patients with adrenal insufficiency

Annet Vulto, Ragnhildur Bergthorsdottir, Martijn van Faassen, Ido P Kema, Gudmundur Johannsson, André P van Beek, Annet Vulto, Ragnhildur Bergthorsdottir, Martijn van Faassen, Ido P Kema, Gudmundur Johannsson, André P van Beek

Abstract

Objective: This study aimed at comparing precursors of endogenous corticosteroid production in patients with primary adrenal insufficiency and in secondary adrenal insufficiency.

Design: Twenty patients with primary adrenal insufficiency and matched controls and 19 patients with secondary adrenal insufficiency participated in this ancillary analysis of two different studies.

Patients and measurements: Patients with primary adrenal insufficiency were on stable hydrocortisone and fludrocortisone therapy. Patients with secondary adrenal insufficiency received two different doses of hydrocortisone in a randomized crossover study. Main outcome measures were concentrations of precursors of cortisol and aldosterone measured by LC-MS/MS RESULTS: Compared to controls, progressively lower concentrations of the glucocorticoid precursors 11-deoxycortisol, 11-deoxycorticosterone and corticosterone concentrations were found in patients with secondary adrenal insufficiency on lower hydrocortisone dose, secondary adrenal insufficiency on higher hydrocortisone dose and primary adrenal insufficiency, respectively. Half of the primary adrenal insufficient patients showed evidence of residual endogenous cortisol or aldosterone synthesis, as determined by quantifiable 11-deoxycortisol, 11-deoxycorticosterone and corticosterone conce ntrations. In secondary adrenal insufficient patients with higher endogenous cortisol production, as indicated by 11-deoxycortisol concentrations above the median, no increased cortisol exposure was observed both by plasma pharmacokinetic parameters and 24-hour free cortisol excretion in urine.

Conclusions: Adrenal corticosteroid production is likely to continue during treatment in a considerable percentage of patients with both primary and secondary adrenal insufficiency. In patients with secondary adrenal insufficiency, this synthesis appears to be sensitive to the dose of hydrocortisone. However, the residual corticosteroid concentrations were quantitatively low and its clinical significance remains therefore to be determined.

Keywords: 11-deoxycortisol; adrenal insufficiency; aldosterone; corticosterone; cortisol; hydrocortisone; precursors.

Conflict of interest statement

The authors declare no conflicts of interest.

© 2019 The Authors. Clinical Endocrinology Published by John Wiley & Sons Ltd.

Figures

Figure 1
Figure 1
Limit of quantification (LOQ). Individual data and the median are plotted

References

    1. Pathogenesis of autoimmune adrenal insufficiency [Internet]. Aug 21, 2017.
    1. Betterle C, Scalici C, Presotto F, et al. The natural history of adrenal function in autoimmune patients with adrenal autoantibodies. J Endocrinol. 1988;117(3):467‐475.
    1. Laureti S, De Bellis A, Muccitelli VI, et al. Levels of adrenocortical autoantibodies correlate with the degree of adrenal dysfunction in subjects with preclinical Addison's disease. J Clin Endocrinol Metab. 1998;83(10):3507‐3511.
    1. De Bellis A, Bizzarro A, Rossi R, et al. Remission of subclinical adrenocortical failure in subjects with adrenal autoantibodies. J Clin Endocrinol Metab. 1993;76(4):1002‐1007.
    1. Smans LC, Zelissen PM. Partial recovery of adrenal function in a patient with autoimmune Addison's disease. J Endocrinol Invest. 2008;31(7):672‐674.
    1. Chakera AJ, Vaidya B. Spontaneously resolving Addison's disease. QJM. 2012;105(11):1113‐1115.
    1. Baxter M, Gorick S, Swords FM. Recovery of adrenal function in a patient with confirmed Addison's disease. Endocrinol Diabetes Metab Case Rep. 2013:130070 10.1530/EDM-13-0070.
    1. Smans LC, Zelissen PM. Does recovery of adrenal function occur in patients with autoimmune Addison's disease? Clin Endocrinol (Oxf). 2011;74(4):434‐437.
    1. Gan EH, MacArthur K, Mitchell AL, et al. Residual adrenal function in autoimmune Addison's disease: improvement after tetracosactide (ACTH1‐24) treatment. J Clin Endocrinol Metab. 2014;99(1):111‐118.
    1. Munro V, Tugwell B, Doucette S, Clarke DB, Lacroix A, Imran SA. Recovery of adrenal function after chronic secondary adrenal insufficiency in patients with hypopituitarism. Clin Endocrinol (Oxf). 2016;85(2):216‐222.
    1. Esteban NV, Yergey AL. Cortisol production rates measured by liquid chromatography/mass spectrometry. Steroids. 1990;55(4):152‐158.
    1. Esteban NV, Loughlin T, Yergey AL, et al. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endocrinol Metab. 1991;72(1):39‐45.
    1. Bergthorsdottir R, Ragnarsson O, Skrtic S, et al. Visceral fat and novel biomarkers of cardiovascular disease in patients with Addison's disease: a case‐control study. J Clin Endocrinol Metab. 2017;102(11):4264‐4272.
    1. Werumeus Buning J, Brummelman P, Koerts J, et al. The effects of two different doses of hydrocortisone on cognition in patients with secondary adrenal insufficiency–results from a randomized controlled trial. Psychoneuroendocrinology. 2015;55:36‐47.
    1. Werumeus Buning J, Touw DJ, Brummelman P, et al. Pharmacokinetics of oral hydrocortisone ‐ results and implications from a randomized controlled trial. Metabolism. 2017;71:7‐16.
    1. Hawley JM, Owen LJ, MacKenzie F, Mussell C, Cowen S, Keevil BG. Candidate reference measurement procedure for the quantification of total serum cortisol with LC‐MS/MS. Clin Chem. 2016;62(1):262‐269.
    1. van Ockenburg SL, Schenk HM, van der Veen A, van Rossum EF, Kema IP, Rosmalen JG. The relationship between 63days of 24‐h urinary free cortisol and hair cortisol levels in 10 healthy individuals. Psychoneuroendocrinology. 2016;73:142‐147.
    1. Reimondo G, Bovio S, Allasino B, Terzolo M, Angeli A. Secondary hypoadrenalism. Pituitary. 2008;11(2):147‐154.
    1. Klose M, Lange M, Kosteljanetz M, Poulsgaard L, Feldt‐Rasmussen U. Adrenocortical insufficiency after pituitary surgery: an audit of the reliability of the conventional short synacthen test. Clin Endocrinol (Oxf). 2005;63(5):499‐505.
    1. Di Dalmazi G, Fanelli F, Mezzullo M, et al. Steroid profiling by LC‐MS/MS in nonsecreting and subclinical cortisol‐secreting adrenocortical adenomas. J Clin Endocrinol Metab. 2015;100(9):3529‐3538.
    1. Keevil BG. Novel liquid chromatography tandem mass spectrometry (LC‐MS/MS) methods for measuring steroids. Best Pract Res Clin Endocrinol Metab. 2013;27(5):663‐674.
    1. Koal T, Schmiederer D, Pham‐Tuan H, Rohring C, Rauh M. Standardized LC‐MS/MS based steroid hormone profile‐analysis. J Steroid Biochem Mol Biol. 2012;129(3–5):129‐138.
    1. Kulle AE, Welzel M, Holterhus PM, Riepe FG. Principles and clinical applications of liquid chromatography ‐ tandem mass spectrometry for the determination of adrenal and gonadal steroid hormones. J Endocrinol Invest. 2011;34(9):702‐708.
    1. Nixon M, Mackenzie SD, Taylor AI, et al. ABCC1 confers tissue‐specific sensitivity to cortisol versus corticosterone: a rationale for safer glucocorticoid replacement therapy. Sci Transl Med. 2016;8(352):352ra109–352ra109.
    1. Schweitzer I, Tuckwell VM, Maguire KP, Tiller JW, Harrison LC, Davies BM. Plasma cortisol and 11‐deoxycortisol activity in depressed patients and normal volunteers. Psychoneuroendocrinology. 1991;16(5):375‐382.
    1. Andrews RC, Rooyackers O, Walker BR. Effects of the 11 beta‐hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab. 2003;88(1):285‐291.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir